Zobrazeno 1 - 10
of 766
pro vyhledávání: '"Naoto T Ueno"'
Autor:
Sudpreeda Chainitikun, Jose Rodrigo Espinosa Fernandez, James P Long, Toshiaki Iwase, Kumiko Kida, Xiaoping Wang, Sadia Saleem, Bora Lim, Vicente Valero, Naoto T Ueno
Publikováno v:
PLoS ONE, Vol 16, Iss 4, p e0250057 (2021)
BackgroundThe current use of targeted therapy plus neoadjuvant chemotherapy for inflammatory breast cancer (IBC) is based on data extrapolated from studies in non-IBC. We conducted a systematic review to determine whether neoadjuvant chemotherapy plu
Externí odkaz:
https://doaj.org/article/eacfe47c019745d09765a013d999b9ec
Autor:
Fanny Le Du, Takeo Fujii, Kumiko Kida, Darren W Davis, Minjeong Park, Diane D Liu, Weiguo Wu, Mariana Chavez-MacGregor, Carlos H Barcenas, Vicente Valero, Debu Tripathy, James M Reuben, Naoto T Ueno
Publikováno v:
PLoS ONE, Vol 15, Iss 3, p e0229903 (2020)
BackgroundTumor cells with a mesenchymal phenotype and/or cancer stem-like cells (CSCs) are known to contribute to metastasis and drug resistance. Circulating tumor cells (CTCs) undergoing epithelial-mesenchymal transition (EMT) and CTCs reflecting a
Externí odkaz:
https://doaj.org/article/ed1d5dea18d847e38b50809efaf6b772
Autor:
Jose Rodrigo Espinosa Fernandez, Bedrich L Eckhardt, Jangsoon Lee, Bora Lim, Troy Pearson, Rob S Seitz, David R Hout, Brock L Schweitzer, Tyler J Nielsen, O Rayne Lawrence, Ying Wang, Arvind Rao, Naoto T Ueno
Publikováno v:
PLoS ONE, Vol 15, Iss 4, p e0231953 (2020)
The original algorithm that classified triple-negative breast cancer (TNBC) into six subtypes has recently been revised. The revised algorithm (TNBCtype-IM) classifies TNBC into five subtypes and a modifier based on immunological (IM) signatures. The
Externí odkaz:
https://doaj.org/article/5e4d94c8b7bd4f518fc97cd1ff769a6f
Autor:
Yohei Funakoshi, Ying Wang, Takashi Semba, Hiroko Masuda, David Hout, Naoto T Ueno, Xiaoping Wang
Publikováno v:
PLoS ONE, Vol 14, Iss 9, p e0222336 (2019)
BackgroundInflammatory breast cancer (IBC) is an aggressive form of breast cancer. The triple-negative subtype of IBC (TN-IBC) is particularly aggressive. Identification of molecular differences between TN-IBC and TN-non-IBC may help clarify the uniq
Externí odkaz:
https://doaj.org/article/fd1b6474b1534ab29f3605eae5681925
Autor:
François Bertucci, Arnaud Guille, Florence Lerebours, Michele Ceccarelli, Najeeb Syed, José Adélaïde, Pascal Finetti, Naoto T. Ueno, Steven Van Laere, Patrice Viens, Alexandre De Nonneville, Anthony Goncalves, Daniel Birnbaum, Céline Callens, Davide Bedognetti, Emilie Mamessier
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-15 (2024)
Abstract Background Neoadjuvant chemotherapy (NACT) became a standard treatment strategy for patients with inflammatory breast cancer (IBC) because of high disease aggressiveness. However, given the heterogeneity of IBC, no molecular feature reliably
Externí odkaz:
https://doaj.org/article/1068ae1848944ff180c01ffd49e76be5
Autor:
Tamer M Fouad, Naoto T Ueno, Robert K Yu, Joe E Ensor, Ricardo H Alvarez, Savitri Krishnamurthy, Anthony Lucci, James M Reuben, Wei Yang, Jie S Willey, Vicente Valero, Melissa L Bondy, Massimo Cristofinalli, Sanjay Shete, Wendy A Woodward, Randa El-Zein
Publikováno v:
PLoS ONE, Vol 13, Iss 9, p e0204372 (2018)
BACKGROUND:To date, studies on inflammatory breast cancer (IBC) lack comprehensive epidemiological data. We analyzed detailed prospectively collected clinical and epidemiological data from the IBC Registry at The University of Texas MD Anderson Cance
Externí odkaz:
https://doaj.org/article/8511d62dbc0747a2b9551bb1c21892e1
Autor:
Kenichi Harano, Ying Wang, Bora Lim, Robert S Seitz, Stephan W Morris, Daniel B Bailey, David R Hout, Rachel L Skelton, Brian Z Ring, Hiroko Masuda, Arvind U K Rao, Steven Van Laere, Francois Bertucci, Wendy A Woodward, James M Reuben, Savitri Krishnamurthy, Naoto T Ueno
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0204513 (2018)
In patients with triple-negative breast cancer (TNBC), tumor-infiltrating lymphocytes (TILs) are associated with improved survival. Lehmann et al. identified 4 molecular subtypes of TNBC [basal-like (BL) 1, BL2, mesenchymal (M), and luminal androgen
Externí odkaz:
https://doaj.org/article/d68e3061b3564009845c351904eed6a8
Autor:
Bedrich L Eckhardt, Maria Gagliardi, LaKesla Iles, Kurt Evans, Cristina Ivan, Xiuping Liu, Chang-Gong Liu, Glauco Souza, Arvind Rao, Funda Meric-Bernstam, Naoto T Ueno, Geoffrey A Bartholomeusz
Publikováno v:
PLoS ONE, Vol 13, Iss 5, p e0195932 (2018)
Inflammatory breast cancer (IBC) is a rare and aggressive presentation of invasive breast cancer with a 62% to 68% 5-year survival rate. It is the most lethal form of breast cancer, and early recognition and treatment is important for patient surviva
Externí odkaz:
https://doaj.org/article/d119af3c583145e6b621239e41d5051c
Autor:
Takeo Fujii, James M Reuben, Lei Huo, Jose Rodrigo Espinosa Fernandez, Yun Gong, Rachel Krupa, Mahipal V Suraneni, Ryon P Graf, Jerry Lee, Stephanie Greene, Angel Rodriguez, Lyndsey Dugan, Jessica Louw, Bora Lim, Carlos H Barcenas, Angela N Marx, Debu Tripathy, Yipeng Wang, Mark Landers, Ryan Dittamore, Naoto T Ueno
Publikováno v:
PLoS ONE, Vol 12, Iss 9, p e0185231 (2017)
Androgen receptor (AR) is frequently detected in breast cancers, and AR-targeted therapies are showing activity in AR-positive (AR+) breast cancer. However, the role of AR in breast cancers is still not fully elucidated and the biology of AR in breas
Externí odkaz:
https://doaj.org/article/03d577abb63d4dd384a30274ba5974ae
Autor:
Arup K Sinha, Jenil R Patel, Yu Shen, Naoto T Ueno, Sharon H Giordano, Debu Tripathy, David S Lopez, Carlos H Barcenas
Publikováno v:
PLoS ONE, Vol 12, Iss 1, p e0170081 (2017)
Cancer outcomes differ depending on where treatment is received. We assessed differences in outcomes in long-term breast cancer survivors at a specialty care hospital by location of their initial treatment.We retrospectively examined a cohort of wome
Externí odkaz:
https://doaj.org/article/b3218d29021d4f6c98c38bebb8ad0e32